myLaminin Perspectives

Clinical trial start-up delays continue to impact site activation, budgets, and timelines due to fragmented workflows across feasibility, contracting, IRB/REB approvals, training, and system readiness. This article explains how CTMS platforms, integrated research systems, and AI-driven automation reduce inefficiencies by centralizing processes, improving visibility, and accelerating trial activation across global clinical research environments.

Rising clinical trial costs are driven by growing protocol complexity, recruitment challenges, site capacity limits, regulatory burdens, and expanding data demands. These inefficiencies strain sponsors and delay outcomes. By adopting quality-by-design, optimizing protocols, improving patient engagement, and leveraging integrated CTMS and RDM platforms, organizations can reduce costs, enhance compliance, and accelerate clinical research while maintaining data integrity.